

2026 SAMPLE CHARACTERISTICS




Between May-July, 902 participants, recruited from all capital cities across Australia, were interviewed.




47 years **Male**

Median age and per cent who identified as male.




Per cent who were unemployed or had no fixed address at the time of interview.




Participants were recruited on the basis that they had injected drugs on at least 6 days in the previous 6 months.


INJECTING-RELATED RISKS AND HARMS




5% of participants reported receptive sharing in the past month, and 8% reported distributive sharing.



Percentage who reported re-using their own needles in the past month.




Percentage who reported injecting someone else in the past month.



28% of participants reported having an injection-related health issue in the past month, stable from 30% in 2025.

OTHER HARMS




The per cent who reported using ≥2 drugs on the day preceding interview, and the 2 most common polysubstance use profiles.



Past year non-fatal overdose remained stable in 2026 relative to 2025.




53% of participants self-reported a mental health problem in the 6 months preceding interview.



Among those who reported a mental health problem, the 3 most common mental health issues were depression, anxiety and PTSD.


NALOXONE AND OTHER HARM REDUCTION STRATEGIES




Knowledge of take-home naloxone and past year naloxone obtained remained stable in 2026 relative to 2025.



36% reported ever using naloxone to resuscitate someone who had overdosed, with 21% having done so in the past year.



Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.




Percentage who reported current drug treatment and health service access for AOD support in the past 6 months.

HEROIN



Past 6 month use of heroin remained stable in 2026 (51%) relative to 2025 (54%).




Of those who had recently consumed heroin, 51% reported daily use, a significant increase from 42% in 2025.



\$50 2025 **\$50** 2026


The median reported price for 1 point of heroin.




Percentage who perceived heroin as being 'easy' or 'very easy' to obtain.

METHAMPHETAMINE

FORM of methamphetamine



Past 6 month use of any methamphetamine, crystal, powder and base remained stable in 2026, relative to 2025.




Of those who had recently used any form of methamphetamine, 79% reported weekly or more frequent use, stable from 2025 (79%).




\$50 2025 **\$50** 2026

The median reported price for 1 point of methamphetamine crystal.




Percentage who perceived methamphetamine crystal as being 'easy' or 'very easy' to obtain.

CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS



Past non-prescribed 6 month use remained stable in 2026 (61%) relative to 2025 (65%).




Of those who had recently used non-prescribed cannabis/cannabinoid-related products, 45% reported daily use, stable from 2025 (50%).



\$20 Hydroponic **\$20** Bush

The median reported price for 1 gram of hydroponic and bush cannabis.




Percentage who perceived cannabis/cannabinoid-related products as being 'easy' or 'very easy' to obtain.


PAST 6 MONTH USE OF OTHER DRUGS

* $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$.


Non-prescribed morphine



Non-prescribed fentanyl



Non-prescribed oxycodone



GHB/GBL/1,4-BD

